Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide"

Mary Lou Affronti^{1

2

3}, James E Herndon 2nd⁴, Mallika P Patel^{5

6}

Affiliations

¹ Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, 047 Baker House, Trent Drive, DUMC Box 3624, Durham, NC, 27710, USA. mary.affronti@duke.edu.
² Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA. mary.affronti@duke.edu.
³ Duke University School of Nursing, Duke University, Durham, NC, USA. mary.affronti@duke.edu.
⁴ Duke Cancer Center Biostatistics, Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA.
⁵ Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.
⁶ Department of Pharmacy, Duke University Hospital, Durham, NC, 27710, USA.

Comment

Mary Lou Affronti et al. Support Care Cancer. 2020 Dec.

. 2020 Dec;28(12):5591-5592.

doi: 10.1007/s00520-020-05726-0. Epub 2020 Sep 3.

Mary Lou Affronti^{1

2

3}, James E Herndon 2nd⁴, Mallika P Patel^{5

6}

¹ Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, 047 Baker House, Trent Drive, DUMC Box 3624, Durham, NC, 27710, USA. mary.affronti@duke.edu.
² Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA. mary.affronti@duke.edu.
³ Duke University School of Nursing, Duke University, Durham, NC, USA. mary.affronti@duke.edu.
⁴ Duke Cancer Center Biostatistics, Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA.
⁵ Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.
⁶ Department of Pharmacy, Duke University Hospital, Durham, NC, 27710, USA.

No abstract available

Comment on

Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.
Patel MP, Woodring S, Randazzo DM, Friedman HS, Desjardins A, Healy P, Herndon JE 2nd, McSherry F, Lipp ES, Miller E, Peters KB, Affronti ML. Patel MP, et al. Support Care Cancer. 2020 May;28(5):2229-2238. doi: 10.1007/s00520-019-05039-x. Epub 2019 Aug 22. Support Care Cancer. 2020. PMID: 31440823 Clinical Trial.
Letter referencing "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting in glioma patients receiving adjuvant temozolomide".
Morio K, Watanabe J, Tsujimoto Y. Morio K, et al. Support Care Cancer. 2020 Dec;28(12):5589. doi: 10.1007/s00520-020-05537-3. Epub 2020 May 27. Support Care Cancer. 2020. PMID: 32458114 No abstract available.